News Column

Biohit Oyj B-shares Subscribed with Stock Options I and II 2013

June 12, 2014

Biohit Oyj Stock Exchange Release June 12, 2014 at 10:40 a.m. (EEST) A total number of 160,000 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 ja II 2013 during May 21June 2, 2014. These shares have been entered into the trade register on June 12, 2014, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading is expected to begin on NASDAQ OMX Helsinki as of June 13, 2014 together with the existing B-shares. The share subscription price was EUR 2.2766 per share with stock options I 2013 and II 2013. The entire subscription price of EUR 364,256 will be credited to the reserve for invested non-restricted equity, and the company share capital remains unchanged. The shares have no nominal value. After the subscription the number of all Biohit Oyj's shares will rise into 13,985,593 shares (13,825,593) and B-shares will rise into 11,010,093 shares (10,850,093). The new shares will correspond to a percentage of 1.1% of Biohit Oyj's total number of shares and 0.23% of the voting rights after registration. The share subscription period with stock options I 2013A began on June 1, 2014 and all the available 100,000 shares were subscribed. The share subscription period with stock options II 2013 began on July 1, 2013 and will end June 30, 2015. The option schemes are based on the Biohit Oyj board resolution of June 19, 2013 and the Annual General Meeting authorization of April 13, 2011. The terms and conditions of the option schemes with additional information are available on Biohit Oyj website at www.biohithealthcare.com. Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fiwww.biohithealthcare.comBiohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com Copyright © 2014 OMX AB (publ).


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: OMX


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters